Compare CNNE & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNNE | SLDB |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.0M | 674.4M |
| IPO Year | 2017 | 2017 |
| Metric | CNNE | SLDB |
|---|---|---|
| Price | $13.69 | $8.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $20.25 | $16.36 |
| AVG Volume (30 Days) | 369.3K | ★ 1.2M |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.47% | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $499,700,000.00 | $8,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $10.46 | $3.79 |
| 52 Week High | $21.96 | $8.87 |
| Indicator | CNNE | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 43.52 | 63.34 |
| Support Level | $12.59 | $6.38 |
| Resistance Level | $15.03 | $8.87 |
| Average True Range (ATR) | 0.52 | 0.51 |
| MACD | -0.13 | 0.14 |
| Stochastic Oscillator | 13.33 | 96.98 |
Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.